A Phase 3, Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Placebo-Controlled Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Buprenorphine (Primary)
- Indications Acute pain; Postoperative pain
- Focus Registrational; Therapeutic Use
- Sponsors INSYS Pharma
- 20 May 2015 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
- 13 Apr 2015 Planned End Date changed from 1 Mar 2015 to 1 May 2015 as reported by ClinicalTrials.gov record.
- 13 Apr 2015 Planned primary completion date changed from 1 Mar 2015 to 1 May 2015 as reported by ClinicalTrials.gov record.